Nathanael Schiander Gray

Nathanael Schiander Gray

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Nathanael Schiander Gray

Stanford University

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
JZJianming Zhang
Jianming Zhang
PYPriscilla L. Yang
Priscilla L. Yang
NGNathanael S. Gray
Nathanael S. Gray

1 March 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CTCarson C. Thoreen
Carson C. Thoreen
SKSeong A. Kang
Seong A. Kang
JCJae Won Chang
Jae Won Chang
QLQingsong Liu
Qingsong Liu
JZJianming Zhang
Jianming Zhang
NGNathanael S. Gray
Nathanael S. Gray
The mammalian target of rapamycin (mTOR) kinase is the catalytic subunit of two functionally distinct complexes, mTORC1 and mTORC2, that coordinately promote cell growth, proliferation, and survival. Rapamycin is a potent allosteric mTORC1 inhibitor with clinical applications as an immunosuppressant and anti-cancer agent. Here we find that Torin1, a highly potent and selective ATP-competitive mTOR inhibitor that directly inhibits both complexes, impairs cell growth and proliferation to a far greater degree than rapamycin. Surprisingly, these effects are independent of mTORC2 inhibition and are instead because of suppression of rapamycin-resistant functions of mTORC1 that are necessary for cap-dependent translation and suppression of autophagy. These effects are at least partly mediated by mTORC1-dependent and rapamycin-resistant phosphorylation of 4E-BP1. Our findings challenge the assumption that rapamycin completely inhibits mTORC1 and indicate that direct inhibitors of mTORC1 kinase activity may be more successful than rapamycin at inhibiting tumors that depend on mTORC1.

2 May 2012 in Nature
Verified
Journal Article
Open access
PDF file
CTCarson C. Thoreen
Carson C. Thoreen
LCLynne Chantranupong
Lynne Chantranupong
HKHeather R. Keys
Heather R. Keys
TWTim Wang
Tim Wang
NGNathanael S. Gray
Nathanael S. Gray
DSDavid M. Sabatini
David M. Sabatini
MTORC1 is shown to regulate a translational program that requires the rapamycin-resistant 4E-BP family of translational repressors and consists almost entirely of mRNAs containing 5′ terminal oligopyrimidine or related motifs. The mTOR pathway is important in the regulation of protein synthesis and is activated in many human cancers. Two papers in this issue of Nature use ribosome profiling to study the control of messenger RNA translation by mTOR signalling. Hsieh et al. find that in prostate cancer cells and mouse prostate tumours, the translation of several genes involved in cancer invasion is regulated by mTOR by means of the 4EBP1 translational repressor. The experimental drug INK128, currently in clinical trials in people with prostate cancer, inhibits mTOR signalling and reduces the progression of prostate cancers to invasive carcinomas in a mouse model. Thoreen et al. show that through the 4E-BP protein family, the mTORC1 kinase recognizes and regulates a subset of mRNAs with an oligopyrimidine motif at the 5′ end. The mTOR complex 1 (mTORC1) kinase nucleates a pathway that promotes cell growth and proliferation and is the target of rapamycin, a drug with many clinical uses1. mTORC1 regulates messenger RNA translation, but the overall translational program is poorly defined and no unifying model exists to explain how mTORC1 differentially controls the translation of specific mRNAs. Here we use high-resolution transcriptome-scale ribosome profiling to monitor translation in mouse cells acutely treated with the mTOR inhibitor Torin 1, which, unlike rapamycin, fully inhibits mTORC1 (ref. 2). Our data reveal a surprisingly simple model of the mRNA features and mechanisms that confer mTORC1-dependent translation control. The subset of mRNAs that are specifically regulated by mTORC1 consists almost entirely of transcripts with established 5′ terminal oligopyrimidine (TOP) motifs, or, like Hsp90ab1 and Ybx1, with previously unrecognized TOP or related TOP-like motifs that we identified. We find no evidence to support proposals that mTORC1 preferentially regulates mRNAs with increased 5′ untranslated region length or complexity3. mTORC1 phosphorylates a myriad of translational regulators, but how it controls TOP mRNA translation is unknown4. Remarkably, loss of just the 4E-BP family of translational repressors, arguably the best characterized mTORC1 substrates, is sufficient to render TOP and TOP-like mRNA translation resistant to Torin 1. The 4E-BPs inhibit translation initiation by interfering with the interaction between the cap-binding protein eIF4E and eIF4G1. Loss of this interaction diminishes the capacity of eIF4E to bind TOP and TOP-like mRNAs much more than other mRNAs, explaining why mTOR inhibition selectively suppresses their translation. Our results clarify the translational program controlled by mTORC1 and identify 4E-BPs and eIF4G1 as its master effectors.

26 March 2018 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
BNBehnam Nabet
Behnam Nabet
JRJustin M. Roberts
Justin M. Roberts
DBDennis L. Buckley
Dennis L. Buckley
JPJoshiawa Paulk
Joshiawa Paulk
SDShiva Dastjerdi
Shiva Dastjerdi
JBJames E. Bradner
James E. Bradner

16 June 2006 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
YLYi Liu
Yi Liu
NGNathanael S Gray
Nathanael S Gray

24 December 2009 in Nature
Verified
Journal Article
Open access
PDF file
WZWenjun Zhou
Wenjun Zhou
DEDalia Ercan
Dalia Ercan
LCLiang Chen
Liang Chen
CYCai-Hong Yun
Cai-Hong Yun
DLDanan Li
Danan Li
PJPasi Antero Jänne
Pasi Antero Jänne
Non-small-cell lung tumours with activating mutations in the epidermal growth factor receptor (EGFR) often show a clinical response to receptor inhibitors, but tend to develop resistance due to the additional EGFR T790M mutations. Pasi Jänne and colleagues now have developed a new class of EGFR inhibitor that selectively inhibits the mutant receptor, rather that the wild type, and also inhibits the T790M mutant. These compounds reduce tumour growth in a mouse model and may prove more clinically effective and better tolerated than current EGFR kinase inhibitors in clinical use. Non-small-cell lung cancers with activating mutations in the epidermal growth factor receptor (EGFR) often show a clinical response to EGFR kinase inhibitors but tend to develop drug-resistance mutations, including the gatekeeper T790M mutation. Here, a new class of EGFR inhibitors is developed; these agents are 30- to 100-fold more potent against EGFR with the T790M mutation, and up to 100-fold less potent against wild-type EGFR, than current EGFR inhibitors. The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation1,2,3. Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are associated with toxicity due to concurrent inhibition of wild-type EGFR4,5. All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR. Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M. These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro. They are also effective in murine models of lung cancer driven by EGFR T790M. Co-crystallization studies reveal a structural basis for the increased potency and mutant selectivity of these agents. These mutant-selective irreversible EGFR kinase inhibitors may be clinically more effective and better tolerated than quinazoline-based inhibitors. Our findings demonstrate that functional pharmacological screens against clinically important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.